

GLAXOSMITHKLINE PLC
Form 6-K
May 10, 2010

FORM 6-K

**SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549**

Report of Foreign Issuer

**Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934**

For period ending May 2010

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the

Yes No x

--

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

.

Date:

10 May 2010

Name of
applicant

GlaxoSmithKline plc

:

Name of scheme:

GlaxoSmithKline Share Option Plan
- Ordinary Shares

Period of return: From:

1 November 2009 To: 30 April
2010

Balance of unallotted
securities under
scheme(s) from previous
return:

5,027,516

Plus:

The amount by which the
block scheme(s) has been
increased since the date 0
of the last return (if any
increase has been applied
for):

Less:

Number of
securities
issued/allotted under
scheme(s) during period
(see LR3.5.7G):

1,831,905

Equals:

Balance under scheme(s)
not yet issued/allotted at
end of period:

3,195,611

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: GlaxoSmithKline Share Option Plan
- ADS
Period of return: From: 1 November 2009 To: 30 April 2010

Balance of unallotted securities under scheme(s) from previous return: 6,025,776

Plus:
The amount by which the block scheme(s) has been increased since the date 0 of the last return (if any increase has been applied for):

Less:
Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 841,634

Equals:
Balance under scheme(s) not yet issued/allotted at end of period: 5,184,142

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: Glaxo Wellcome UK Share Option Scheme
Period of return: From: 1 November 2009 To: 30 April 2010

Balance of unallotted securities under scheme(s) from previous return: 5,119,750

Plus:
The amount by which the block scheme(s) has been increased since the date 0 of the last return (if any increase has been applied for):

Less:
Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals:
Balance under scheme(s) not yet issued/allotted at end of period: 5,119,750

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: Glaxo Wellcome International Share Option Scheme
Period of return: From: 1 November 2009 To: 30 April 2010

Balance of unallotted securities under scheme(s) from previous return: 13,267,156

Plus:
The amount by which the block scheme(s) has been increased since the date 0 of the last return (if any increase has been applied for):

Less:
Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals: 13,267,156

Balance under scheme(s)
not yet issued/allotted at
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: Glaxo Wellcome 1999 Share
Option Plan
Period of return: From: 1 November 2009 To: 30 April
2010

Balance of unallotted securities under scheme(s) from previous return: 1,040,000

Plus:
The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): 0

Less: 0
Number of securities

issued/allotted under
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under scheme(s) 1,040,000
not yet issued/allotted at
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

.

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: SmithKline Beecham 1989
Executive Share Option Plan -
Approved - Ordinary Shares
Period of return: From: 1 November 2009 To: 30 April
2010

Balance of unallotted
securities under
scheme(s) from previous
return: 163,606

Plus:
The amount by which the
block scheme(s) has been
increased since the date 0
of the last return (if any
increase has been applied
for):

Less:
Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0
Equals:
Balance under scheme(s) not yet issued/allotted at end of period: 163,606

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: SmithKline Beecham 1989 Executive Share Option Plan - Unapproved - ADS
Period of return: From: 1 November 2009 To: 30 April 2010
Balance of unallotted securities under scheme(s) from previous return: 275,420
Plus: 0
The amount by which the block scheme(s) has been

increased since the date
of the last return (if any
increase has been applied
for):

Less:

Number of
securities
issued/allotted under 0
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under scheme(s)
not yet issued/allotted at 275,420
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: SmithKline Beecham 1989
Executive Share Option Plan -
Unapproved - Ordinary
Period of return: From: 1 November 2009 To: 30 April 2010
Balance of unallotted securities under scheme(s) from previous return: 100,000
Plus: 0

The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

Less:

Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G): 0

Equals:

Balance under scheme(s) not yet issued/allotted at end of period: 100,000

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

BLOCK LISTING SIX MONTHLY RETURN

Information provided on this form must be typed or printed electronically and provided to an
ris

.

Date:
10 May 2010

Name of applicant: GlaxoSmithKline plc
:
Name of scheme: GlaxoSmithKline Savings Related Share Option Scheme
Period of return: From: 1 November 2009 To: 30 April 2010
Balance of unallotted securities under scheme(s) from previous return: 5,191,246

Plus:

The amount by which the
block scheme(s) has been
increased since the date 0
of the last return (if any
increase has been applied
for):

Less:

Number of
securities 731,368
issued/allotted under
scheme(s) during period
(see LR3.5.7G):

Equals:

Balance under scheme(s)
not yet issued/allotted at 4,459,878
end of period:

Name of contact: Victoria Whyte
Telephone number of contact: 020 8047 5000

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: May 10, 2010

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc